EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy

J Bradley Layton iD, Colin Anderson-Smits iD, Zhongwen Huang, Hakan Ay, William Spalding, Bilal Khokhar, Jie Zhou, Lee Bennett, Mary S Anthony iD

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70124 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von J Bradley Layton und 8 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, North Carolina, USA. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Immune globulin infusion (human) 10% solution (GAMMAGARD LIQUID; GGL), an intravenous immunoglobulin (IVIG), has recently received U.S. approval for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We evaluated thrombotic events, acute kidney injury (AKI), and hemolytic events among patients with CIDP initiating IVIG treatment with GGL, versus a U.S.‐approved IVIG comparator for CIDP, in individual and combined cohorts of immunoglobulin (Ig)‐naive and Ig‐experienced participants.

Methods

This active‐comparator, new‐user, cohort study of patients with CIDP used the Merative MarketScan Research and Optum Clinformatics Data Mart databases (2008–2019). Outcomes were compared between adults receiving GGL and comparator IVIGs within propensity score‐weighted samples using hazard ratios (HRs) and time period‐specific risk ratios (RRs) and risk differences (RDs) with 95% confidence intervals (CI). Database‐specific results were meta‐analyzed and appropriate.

Results

Data from eligible patients in MarketScan (GGL, n = 1441; comparators, n = 2708) and Optum (GGL, n = 644; comparators, n = 1293) were analyzed. Across both databases, HRs, 1‐year RRs, and 1‐year RDs for thrombotic events did not suggest consistent differences in risk across treatment groups (e.g., MarketScan combined cohort: RR 1.14 [95% CI, 0.50 to 2.55]; Optum combined cohort: 0.60 [0.25 to 1.54]). Similarly, there was no difference in AKI risk between groups (e.g., MarketScan combined cohort: RR 1.25 [95% CI, 0.65 to 2.54]; Optum combined cohort: 0.65 [0.22 to 1.94]). Hemolytic events were rare.

Conclusions

Thrombotic events, AKI, and hemolytic events were rare among patients with CIDP receiving IVIG. There were no consistently different outcome risks between patients receiving GGL versus other IVIGs with US approval for CIDP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmunoglobulins, IntravenousHumansMaleFemaleMiddle AgedAdultAgedCohort StudiesDatabases, FactualUnited StatesAcute Kidney InjuryThrombosisPropensity ScoreRetrospective Studies

Stichwörter der Autor:innen

acute kidney injurychronic inflammatory demyelinating polyradiculoneuropathydatabase studyhemolytic eventsimmune globulin infusion (human) 10% solutionintravenous immunoglobulin therapiesoutcome risksafetythrombotic events

Substanzen

Immunoglobulins, Intravenous

Autor:innen und Institutionen

  • RTI Health Solutions, Research Triangle Park, North Carolina, USA.
  • Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.

ORCID-Profile: J Bradley Layton, Colin Anderson-Smits, Mary S Anthony

Förderung

  • Takeda Development Center Americas, Inc

Zitieren

APA

Layton, J. B., Anderson-Smits, C., Huang, Z., Ay, H., Spalding, W., Khokhar, B., Zhou, J., Bennett, L., & Anthony, M. S. (2025). A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70124

Vancouver

Layton JB, Anderson-Smits C, Huang Z, Ay H, Spalding W, Khokhar B, et al. A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70124

BibTeX
@article{Layton2025,
  author = {Layton, J Bradley and Anderson-Smits, Colin and Huang, Zhongwen and Ay, Hakan and Spalding, William and Khokhar, Bilal and Zhou, Jie and Bennett, Lee and Anthony, Mary S},
  title = {A Comparative Real‐World Study Evaluating the Safety of Immune Globulin Infusion (Human) 10% Solution and Other Intravenous Immunoglobulin Therapies for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70124}
}
Kostenlos starten →